Complicaciones post quirúrgicas y factores de riesgo en pacientes con Leucemia Mieloide Aguda

Palabras clave: Leucemia mieloide aguda, Complicaciones, Hemorragia, Factores de riesgo, Cirugía

Resumen

Las leucemias son un tipo de desorden maligno (cáncer) que inicia en las células madre que dan origen a los diferentes linajes de células sanguíneas, es un cáncer de la sangre y médula ósea. La mayoría de las leucemias se originan en formas tempranas de los leucocitos; aunque algunos otros tipos de leucemias inician en otros tipos de células sanguíneas. Los pacientes que presentan leucemia mieloide aguda (AML) tienen más comorbilidades y tasas mayores de complicaciones. Muchos de estos pacientes son llevados a cirugía debido a diferentes factores, ya sea por la enfermedad (AML) o por comorbilidades que presenten; después de esos procedimientos muchos pacientes presentan complicaciones como hemorragias, trombos, infecciones, etc. que pueden comprometer órganos vitales e incluso la vida

Biografía del autor/a

Sebastian Cerón-Luna, Universidad Pontificia Bolivariana

Estudiante de medicina

Citas

Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010; 28(17):2847-2852. DOI: 10.1200/JCO.2009.25.2395

McCullough KB, Patnaik MM. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes - Advances in treatment. Best Pract Res Clin Haematol. 2020; 33(2):101130.

Young AL, Tong RS, Birmann BM, Druley TE. Clonal hematopoiesis and risk of acute myeloid leukemia. Haematologica. 2019; 104(12):2410-2417. DOI: 10.3324/haematol.2018.215269

Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019; 36:70-87. DOI: 10.1016/j.blre.2019.04.005

Dhopeshwarkar N, Iqbal S, Wang X, Salas M. A Retrospective Study of Comorbidities and Complications in Elderly Acute Myeloid Leukemia Patients in the United States. Clin Lymphoma Myeloma Leuk. 2019; 19(8):436-456. DOI: 10.1016/j.clml.2019.04.012

Blum W, Bloomfield CD. Acute Myeloid Leukemia. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 20. ed. New York, NY: McGraw-Hill Education; 2018

Vosberg S, Greif PA. Clonal evolution of acute myeloid leukemia from diagnosis to relapse. Genes Chromosomes Cancer. 2019; 58(12):839-849. DOI: 10.1002/gcc.22806

Chen P, Zhan W, Wang B, et al. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells. Exp Cell Res. 2019; 376(2):114-123. DOI: 10.1016/j.yexcr.2019.02.008

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442

El-Khazragy N, Elayat W, Matbouly S, et al. The prognostic significance of the long non-coding RNAs “CCAT1, PVT1” in t(8;21) associated Acute Myeloid Leukemia. Gene. 2019; 707:172-177. DOI: 10.1016/j.gene.2019.03.055

Howlader N, Noone AM, Krapcho M, Miller D, Brest A, et al. SEER Cancer Statistics Review (CSR) 1975-2016. Bethesda: National Cancer Institute; 2019. Disponible en: https://seer.cancer.gov/csr/1975_2016/

Abuelgasim KA, Albuhayri B, Munshi R, Mugairi AA, Alahmari B, et al. Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review. Leuk Res Rep. 2020; 14:100206

Griffiths EA, Carraway HE, Chandhok NS, Prebet T. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. Leuk Res. 2020; 91:106339. DOI: 10.1016/j.leukres.2020.106339

Bewersdorf JP, Shallis RM, Wang R, et al. Healthcare expenses for treatment of acute myeloid leukemia. Expert Rev Hematol. 2019; 12(8):641-650. DOI: 10.1080/17474086.2019.1627869

Molica M, Breccia M, Foa R, Jabbour E, Kadia TM. Maintenance therapy in LMA: The past, the present and the future. Am J Hematol. 2019; 94(11):1254-1265. DOI: 10.1002/ajh.25620

Papayannidis C, Sartor C, Marconi G, et al. Acute Myeloid Leukemia Mutations: Therapeutic Implications. Int J Mol Sci. 2019; 20(11):2721. DOI: 10.3390/ijms20112721

Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020. DOI: 10.1016/j.annonc.2020.02.018

Ho G, Jonas BA, Li Q, Brunson A, Wun T, et al. Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. Br J Haematol. 2017; 177(5):791-799. DOI: 10.1111/bjh.14631

Wang J, Chen R, Lin X, Wang Y, Wang JH, et al. New perspectives on treatment strategies for patient with acute myeloid leukemia and complex karyotype abnormalities after percutaneous coronary intervention. 2019; 98(30). DOI: 10.1097/MD.0000000000016586

Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019; 33(2):379-389. DOI: 10.1038/s41375-018-0312-9

Niu P, Yao B, Wei L, Zhu H, Fang C, Zhao Y. Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia. Blood Cells Mol Dis. 2019; 77:43-50

Desai P, Hassane D, Roboz GJ. Clonal Hematopoiesis and risk of Acute Myeloid Leukemia. Best Pract Res Clin Haematol. 2019; 32(2):177-185. DOI: 10.1016/j.beha.2019.05.007

Fateen MA, El Demerdash DM, Zayed RA, Mattar MM. Role of physical function in predicting short-term treatment outcome in Egyptian acute myeloid leukemia patients: a single center experience. Hematol Transfus Cell Ther. 2019; 41(1):17-24. DOI: 10.1016/j.htct.2018.05.003

Rick Alteri, Mamta Kalidas, Lynn Yadao, Cynthia Ogoro, et al. Cancer Surgery. Atlanta, Georgia: American Cancer Society; 2019. Disponible en:https://www.cancer.org/es/tratamiento/tratamientos-y-efectos-secundarios/tipos-de-tratamiento/cirugia/riesgos-de-la-cirugia-del-cancer.html

Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013; 381(9865):484-495. DOI: 10.1016/S0140-6736(12)61727-9

Snavely C, Habboushe J. Myopericarditis as a Presenting Feature of Acute Myeloid Leukemia. J Emerg Med. 2020; 0736-4679(20)30343-7

Peacock O, Waters PS, Otero de Pablos J, et al. A systematic review of risk-reducing cancer surgery outcomes for hereditary cancer syndromes. Eur J Surg Oncol. 2019; 45(12):2241-2250. DOI: 10.1016/j.ejso.2019.06.034

Shallis RM, Boddu PC, Bewersdorf JP, Zeidan AM. The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Rev. 2020; 40:100639. DOI: 10.1016/j.blre.2019.100639

Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017; 18(1):112-121. DOI: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4. PMID: 27927582; PMCID: PMC7771361.

Santini V, Ossenkoppele GJ. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. Crit Rev Oncol Hematol. 2019; 140:1-7. DOI: 10.1016/j.critrevonc.2019.05.013

Brierley CK, Staves J, Roberts C, et al. The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia. Transfusion. 2019; 59(7):2248-2254. DOI: 10.1111/trf.15397

Ebrahimi M, Allahyari A, Ebrahimi M, et al. Effects of Dietary Honey andArdehCombination on Chemotherapy- Induced Gastrointestinal and Infectious Complications in Patients with Acute Myeloid Leukemia: A Double-Blind Randomized Clinical Trial. Iran J Pharm Res. 2016; 15(2):661-668

Ma WW, Kasyanju Carrero LM, Yin XF, Liu HF, Zhou BR. Acute myeloid leukemia with adult atopic dermatitis as first manifestation. Medicine. 2019; 98(32):16362. DOI: 10.1097/MD.0000000000016362

Percival MM, Estey EH. Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. Cancer. 2019; 125(18):3121-3130. DOI: 10.1002/cncr.32354

Nunes AL, Paes CA, Murao M, Viana MB, De Oliveira BM. Cytogenetic abnormalities, WHO classification, and evolution of children and adolescents with acute myeloid leukemia. Hematol Transfus Cell Ther. 2019; 41(3):236-243. DOI: 10.1016/j.htct.2018.09.007

DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019; 133(1):7-17. DOI: 10.1182/blood-2018-08-868752

Luger SM. Acute myeloid leukemia: How to treat the fit patient over age 75?. Best Pract Res Clin Haematol. 2019; 32(4):101105. DOI: 10.1016/j.beha.2019.101105

Willis C, Menon J, Unni S, et al. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. Leuk Res. 2019; 87:106262. DOI: 10.1016/j.leukres.2019.106262

Thoms JAI, Beck D, Pimanda JE. Transcriptional networks in acute myeloid leukemia. Genes Chromosomes Cancer. 2019; 58(12):859-874. DOI: 10.1002/gcc.22794

Ciftciler R, Demiroglu H, Haznedaroglu IC, et al. Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019; 19(11):729-734. DOI: 10.1016/j.clml.2019.08.007

Ciftciler R, Demiroglu H, Buyukasık Y, Aksu S, Goker H. Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019; 19(5):205-212. DOI: 10.1016/j.clml.2018.12.006

Brunner AM, Blonquist TM, DeAngelo DJ, et al. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020; 7(2):122-133. DOI: 10.1016/S2352-3026(19)30203-0

Portugal RD, Nucci MLM. Current treatment preferences in acute myeloid leukemia: a survey in Brazil. Hematol Transfus Cell Ther. 2019; 2531-1379(19):30131-2. DOI: 10.1016/j.htct.2019.07.005

Shimoni A, Labopin M, Savani B, et al. Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019; 25(11):2251-2260. DOI: 10.1016/j.bbmt.2019.06.031

Rashidi A, Hamadani M, Zhang MJ, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019; 3(12):1826-1836. DOI: 10.1182/bloodadvances.2019000050

Sissung TM, Figg WD. Stem cell clinics: risk of proliferation. Lancet Oncol. 2020; 21(2):205-206. DOI: 10.1016/S1470-2045(19)30787-9

Stratmann J, van Kann E, Rummelt C, et al. Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. Leuk Res. 2019; 85:106192. DOI: 10.1016/j.leukres.2019.106192

Brunner AM, Blonquist TM, DeAngelo DJ, McMasters M, Fell G, et al. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematology. 2020; 7(2):122-133

Marcault C, Venton G, Gastaud L, et al. Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines. Clin Lymphoma Myeloma Leuk. 2020; 20(2):76-81. DOI: 10.1016/j.clml.2019.11.016

Le Floch AC, Eisinger F, D’Incan E, et al. Socioeconomic deprivation is associated with decreased survival in patients with acute myeloid leukemia. Cancer Epidemiol. 2020; 66:101699. DOI: 10.1016/j.canep.2020.101699

Welch JS. Novel Strategies in High-Risk LMA. Clinical Lymphoma, Myeloma & Leukemia. 2019; 19:82-85

Publicado
2021-06-23
Cómo citar
Cerón-Luna, S. (2021). Complicaciones post quirúrgicas y factores de riesgo en pacientes con Leucemia Mieloide Aguda. Salutem Scientia Spiritus, 7(2), 47-53. Recuperado a partir de https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/2374